Gastric cancer treatment: recent progress and future perspectives
WL Guan, Y He, RH Xu - Journal of hematology & oncology, 2023 - Springer
Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …
Signaling pathways and therapeutic interventions in gastric cancer
Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …
Despite tremendous progress in diagnosis and therapeutic strategies and significant …
Zolbetuximab plus CAPOX in CLDN18. 2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …
Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro …
Background Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.
2), has shown efficacy in patients with CLDN18. 2-positive, human epidermal growth factor …
2), has shown efficacy in patients with CLDN18. 2-positive, human epidermal growth factor …
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro …
X Zhang, H Liang, Z Li, Y Xue, Y Wang, Z Zhou… - The Lancet …, 2021 - thelancet.com
Background The optimal perioperative chemotherapeutic regimen for locally advanced
gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and …
gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and …
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or …
Z Tang, Y Wang, D Liu, X Wang, C Xu, Y Yu… - Nature …, 2022 - nature.com
The synergistic effect of neoadjuvant immunotherapy and chemoradiotherapy in gastric
adenocarcinoma is unclear. This phase II trial (NCT03631615) investigated this neoadjuvant …
adenocarcinoma is unclear. This phase II trial (NCT03631615) investigated this neoadjuvant …
Prognostic and predictive value of a pathomics signature in gastric cancer
D Chen, M Fu, L Chi, L Lin, J Cheng, W Xue… - Nature …, 2022 - nature.com
The current tumour-node-metastasis (TNM) staging system alone cannot provide adequate
information for prognosis and adjuvant chemotherapy benefits in patients with gastric cancer …
information for prognosis and adjuvant chemotherapy benefits in patients with gastric cancer …
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric …
X Qu, B Liu, L Wang, L Liu, W Zhao, C Liu, J Ding… - Drug Resistance …, 2023 - Elsevier
Abstract Aims Long non-coding RNAs (lncRNAs), as one of the components of exosomes
derived from cancer-associated fibroblasts (CAFs), exhibit a crucial role in the pathogenesis …
derived from cancer-associated fibroblasts (CAFs), exhibit a crucial role in the pathogenesis …
The landscape of cancer research and cancer care in China
Z Lu, Y Chen, D Liu, X Jiao, C Liu, Y Wang, Z Zhang… - Nature Medicine, 2023 - nature.com
The rising cancer incidence rate in China poses a substantial public health concern,
although there have been remarkable improvements in the country's cancer mortality and …
although there have been remarkable improvements in the country's cancer mortality and …
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm …
J Wei, X Lu, Q Liu, Y Fu, S Liu, Y Zhao, J Zhou… - Nature …, 2023 - nature.com
In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally
advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti …
advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti …